Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement
May 28, 2019 at 11:12 AM EDT
UBS analyst Navin Jacob also cut his stock price target to $12 from $22.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
